Shares of Virios Therapeutics, Inc. (VIRI) are rising more than 14% Wednesday morning.
The company today said the data from the Phase 2a study of its investigational antiviral therapy IMC-1 in fibromyalgia showed that IMC-1 was better tolerated than placebo in patients with fibromyalgia.
Fibromyalgia is a chronic rheumatic condition that causes pain throughout the body.
The company said, this result is highlighted in a poster presentation at the International Association for the Study of Pain (IASP) World Congress, being held virtually June 9 - 11, 2021 and June 16 - 18, 2021.
VIRI is currently at $6.41. It has traded in the range of $4.60- $16.71 in the last one year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.